CA3236153A1 - Poegma-based lipid nanoparticles - Google Patents

Poegma-based lipid nanoparticles Download PDF

Info

Publication number
CA3236153A1
CA3236153A1 CA3236153A CA3236153A CA3236153A1 CA 3236153 A1 CA3236153 A1 CA 3236153A1 CA 3236153 A CA3236153 A CA 3236153A CA 3236153 A CA3236153 A CA 3236153A CA 3236153 A1 CA3236153 A1 CA 3236153A1
Authority
CA
Canada
Prior art keywords
lipid
mol
lipid nanoparticle
poegma
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236153A
Other languages
English (en)
French (fr)
Inventor
Ashutosh Chilkoti
Soumen Saha
Parul SIROHI
Angus Hucknall
Sonal Deshpande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CA3236153A1 publication Critical patent/CA3236153A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3236153A 2021-10-25 2022-10-25 Poegma-based lipid nanoparticles Pending CA3236153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271595P 2021-10-25 2021-10-25
US63/271,595 2021-10-25
PCT/US2022/078659 WO2023076902A1 (en) 2021-10-25 2022-10-25 Poegma-based lipid nanoparticles

Publications (1)

Publication Number Publication Date
CA3236153A1 true CA3236153A1 (en) 2023-05-04

Family

ID=86158533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236153A Pending CA3236153A1 (en) 2021-10-25 2022-10-25 Poegma-based lipid nanoparticles

Country Status (6)

Country Link
US (1) US20250049729A1 (https=)
EP (1) EP4422605A4 (https=)
JP (1) JP2024541924A (https=)
CN (1) CN118201605A (https=)
CA (1) CA3236153A1 (https=)
WO (1) WO2023076902A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117562869B (zh) * 2023-05-05 2024-07-16 中南大学湘雅医院 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用
WO2025067389A1 (en) * 2023-09-28 2025-04-03 Immorna (hangzhou) Biotechnology Co., Ltd. Lipid complex nanoparticle for lung-targeted delivery of nucleic acid therapeutic agent
WO2025081189A1 (en) * 2023-10-12 2025-04-17 Georgia Tech Research Corporation Methods and compositions for lipid nanoparticle (lnp) mediated delivery of mrna encoded synthetic antigens for universal tumor targeting by car t cells
CN118001253A (zh) * 2024-02-07 2024-05-10 北京大学 一种肾脏靶向mRNA-LNP递送技术和疾病治疗方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799565B2 (en) * 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US8497356B2 (en) 2009-02-17 2013-07-30 Duke University Biomolecule polymer conjugates and methods for making the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017112825A2 (en) 2015-12-21 2017-06-29 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2020051220A1 (en) 2018-09-04 2020-03-12 The Board of the Regents of the University of Texas System Compositions and methods for organ specific delivery of nucleic acids
CN112996519B (zh) * 2018-09-04 2025-02-28 德克萨斯大学系统董事会 用于核酸的器官特异性递送的组合物和方法
AU2021232069A1 (en) * 2020-03-05 2022-11-03 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome
MX2023000806A (es) * 2020-07-17 2023-04-11 Generation Bio Co Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos.
CN112961065B (zh) * 2021-02-05 2023-03-14 嘉晨西海(杭州)生物技术有限公司 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
WO2022212911A1 (en) 2021-04-01 2022-10-06 Duke University Poegma copolymer conjugates and methods of treating diseases

Also Published As

Publication number Publication date
US20250049729A1 (en) 2025-02-13
CN118201605A (zh) 2024-06-14
WO2023076902A1 (en) 2023-05-04
JP2024541924A (ja) 2024-11-13
EP4422605A4 (en) 2025-06-18
EP4422605A1 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
US20250049729A1 (en) Poegma-based lipid nanoparticles
JP2023549011A (ja) 遺伝子編集のための脂質製剤
US9080186B2 (en) Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
WO2010056403A1 (en) Branched cationic lipids for nucleic acids delivery system
EP2304026A2 (en) Nanoparticle compositions for nucleic acids delivery system
US20110229581A1 (en) Releasable cationic lipids for nucleic acids delivery systems
WO2022140404A1 (en) Zwitterionic lipid nanoparticle compositions, and methods of use
EP2362728A1 (en) Releasable polymeric lipids for nucleic acids delivery system
EP4520349A1 (en) Interfering rna for inhibiting b7-h3 gene expression and use thereof
JP2012509273A (ja) 核酸送達系のための放出可能融合性脂質
EP4630061A1 (en) Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid
WO2024086929A1 (en) Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
KR101685304B1 (ko) 간 조직 특이적 유전자 발현 억제인자 전달용 나노리포좀
CN117264955A (zh) 一种抑制top1基因表达的干扰rna及其应用
CN120271651A (zh) 一种用于核酸递送的可电离阳离子脂质化合物和组合物及其应用
WO2025010554A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
WO2025043730A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and use thereof
WO2025072150A1 (en) Zwitterionic lipid nanoparticle compositions, and methods of use
WO2025264883A1 (en) Anionic lipid nanoparticles for nucleic acid delivery
CN121872965A (zh) 脂质化合物和脂质纳米颗粒组合物
CN121698795A (zh) 脂质化合物和脂质纳米颗粒组合物
WO2026084761A2 (en) Conformationally tunable lipid compositions and therapeutic uses thereof
EP4680287A1 (en) Delivery of gene editing systems and methods of use thereof
WO2025102261A1 (zh) 递送治疗剂的脂质化合物及其制备方法与应用
CN121872927A (zh) 脂质化合物和脂质纳米颗粒组合物

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017